Tarsus Pharmaceuticals (NASDAQ:TARS) Cut to Hold at Wall Street Zen

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Thursday.

TARS has been the subject of a number of other reports. HC Wainwright reaffirmed a "buy" rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Barclays reduced their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Oppenheimer increased their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Guggenheim boosted their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a report on Monday, May 5th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $66.33.

Tarsus Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ TARS traded up $0.35 during midday trading on Thursday, hitting $43.54. The stock had a trading volume of 53,691 shares, compared to its average volume of 697,295. The company has a fifty day moving average price of $47.88 and a 200 day moving average price of $49.15. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -11.47 and a beta of 0.94. Tarsus Pharmaceuticals has a 1-year low of $20.08 and a 1-year high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. On average, analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 2,137 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $107,085.07. Following the completion of the sale, the insider now owns 46,355 shares of the company's stock, valued at approximately $2,322,849.05. The trade was a 4.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Bryan Wahl sold 3,084 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $154,539.24. Following the sale, the general counsel now directly owns 51,712 shares in the company, valued at approximately $2,591,288.32. This represents a 5.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock worth $1,581,173 in the last 90 days. 8.25% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $25,000. GF Fund Management CO. LTD. bought a new position in Tarsus Pharmaceuticals during the 4th quarter worth $44,000. R Squared Ltd bought a new position in Tarsus Pharmaceuticals during the 4th quarter worth $53,000. Amalgamated Bank increased its position in Tarsus Pharmaceuticals by 30.1% in the first quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after buying an additional 295 shares during the period. Finally, Quarry LP bought a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at $166,000. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.